Traduction de «for this indication was accepted in april » (Néerlandais → Français) :

A regulatory submission for this indication was accepted in April in China.
La Chine a délivré, en avril, une autorisation pour cette indication.

Selected projects awaiting regulatory decisions Completed submissions Product Indication US EU Japan News update ABF656 Hepatitis C Q4 2009 - Dossier for ABF656 at once-everytwo-weeks dosing was withdrawn in EU in April since additional information would be requested that could not be generated within required timeframe
Projets importants en attente de décisions réglementaires Demandes déposées Produit Indication USA UE Japon Mise à jour ABF656 Hépatite C T4 2009 - Le dossier d’ABF656 comportant une dose unique toutes les 2 semaines a été retiré de l’UE en avril, car l’information supplémentaire requise ne pouvait pas être fournie dans le délai imparti

the performance of health systems can be found in Supplement S2 of this report. The whole set of indicators was then reviewed by the research team to avoid redundancies in indicators and enhance the consistency of the set.
The whole set of indicators was then reviewed by the research team to avoid redundancies in indicators and enhance the consistency of the set.

Exforge HCT, which adds a diuretic to this combination, was launched in the US after regulatory approval in April 2009 as a high blood pressure therapy with three medicines in one pill.
Exforge HCT, qui ajoute un diurétique à cette association, a été lancé aux Etats-Unis où il a été autorisé, en avril 2009, en tant que traitement contre l’hypertension associant trois médicaments en un comprimé unique.

Alcon’s closing share price was USD 148.44 on April 4, the last trading day before the signing of this agreement.
Le 4 avril, dernier jour de négoce avant la signature de cet accord, le cours de clôture de l’action Alcon s’est élevé à USD 148,44.

Gleevec/Glivec, a targeted therapy for certain forms of CML and GIST, was approved in 2009 for use in adjuvant treatment of patients following complete gross resection of GIST and has since received approvals for this indication in more than 55 countries.
Glivec/Gleevec, un traitement ciblé contre certaines formes de LMC et de GIST, a été homologué en 2009 pour son utilisation comme adjuvant dans les résections complètes de GIST et a depuis été autorisé pour cette indication dans plus de 55 pays.

A dossier for EU approval of Afinitor (everolimus) in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis was also filed in July 2010; the FDA granted everolimus priority review for this indication. The FDA action date is October 29.
contre l’astrocytome sous épendymaire à cellules géantes associé à une sclérose tubéreuse; la FDA a accordé à évérolimus le statut de revue prioritaire pour cette indication, et sa décision est attendue pour le 29 octobre.

114 These data are not presented in detail in this report. 8.2.2.2 Inequalities in the indicators of accessibility The percentage of households reporting to have delayed contacts with the health system for financial reasons was strongly related to the income level, with 27% of delay in the households of the lowest quintile versus 4%
8.2.2.2 Inequalities in the indicators of accessibility The percentage of households reporting to have delayed contacts with the health system for financial reasons was strongly related to the income level, with 27% of delay in the households of the lowest quintile versus 4%

It is computed as the difference between the overall rate in the population and the rate in the more advantaged group, dividedd by the overall rate in the population. In this chapter, we highlighted the indicators for which we observed a relative risk (RR) as large as 1.2 (or 0.83 when the gradient was reverse).
It is computed as the difference between the overall rate in the population and the rate in the more advantaged group, divided by the overall rate in the population.

Gleevec/Glivec, a targeted therapy for certain forms of CML and GIST, was approved in 2009 for use in adjuvant GIST and has since received approvals for this indication in more than 55 countries.
Glivec/Gleevec, un traitement ciblé contre certaines formes de LMC et de GIST, a été homologué en 2009 pour son utilisation comme adjuvant dans les GIST et a depuis été autorisé pour cette indication dans plus de 55 pays.